Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
Precision Perspectives: Navigating Advancements in HR+ / HER2 Negative Breast Cancer Care : Episode 7
Highlighting the Available CDK4/6 Inhibitors
Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.
EP: 1.Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 2.Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer
EP: 3.CDK4/6 Inhibitors as First-Line Options in Metastatic Breast Cancer
EP: 4.Treatment Algorithms for Early and Metastatic Breast Cancer
EP: 5.NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer
EP: 6.Evaluating the Impact of Metastatic Breast Cancer on Patients
Now Viewing
EP: 7.Highlighting the Available CDK4/6 Inhibitors
EP: 8.Strategies to Enhance CDK4/6 Inhibitor Adherence in mBC
EP: 9.Applying NCCN Guidelines in the Treatment of mBC
EP: 10.CDK4/6 Inhibitor Sequencing and NCCN Guidelines in mBC
EP: 11.Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
EP: 12.Navigating Financial Barriers: Cost-Saving Strategies and Patient Assistance Programs
EP: 13.Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer
EP: 14.Academic and Community Practice Collaboration in mBC Treatment
EP: 15.Defining the Standard of Care for Early Breast Cancer Treatment
EP: 16.Balancing Clinical and Economic Factors in Early Breast Cancer Treatment
EP: 17.Alternative Treatments for eBC and mBC
EP: 18.Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
EP: 19.Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care
EP: 20.Key Takeaways on mBC and eBC
Recent Videos
Related Content
